Skip to main content
. 2023 Oct 28;13(11):1587. doi: 10.3390/biom13111587

Table 1.

KRAS G12C inhibitors and combination treatments.

Number Combination Clinical Study Reference
1 Adagrasib + immune checkpoint inhibitor pembrolizumab Yes [28]
2 Sotorasib + MEK inhibitor trametinib Yes [29]
3 Sotorasib + proteasome inhibitor carfilzomib No [30]
4 Adagrasib + proteasome inhibitor carfilzomib No [30]